Roivant Sciences Ltd.ROIV

Roivant Sciences Ltd. may market itself as a biotech innovator with a glittering pipeline and a management desks that could moonlight on a *Fortune* cover, but the hard numbers filed with the SEC tell a different story. For the year to 31 March 2026, the company reported revenue of $8.3 million from customers, an operating loss of $515.1 million, a net loss of $299.8 million, and negative operating cash flow of $750.3 million. Cash and cash equivalents stood at $1.42 billion, while research and development spending gobbled up $681.8 million like a firehose aimed at a thimble. The company’s stockholders’ equity was $4.53 billion, but that figure masks a top-line so thin it could be mistaken for a PhD student’s stipend.

In product terms, Vtama-an FDA-approved topical cream for plaque psoriasis-is the closest thing Roivant has to a revenue engine. The company trumpets third-quarter sales of $21 million as evidence the pipeline is already printing cash, but $21 million is barely enough to cover a single month of operating cash burn, let alone fund the $681.8 million R&D budget. The company also points to RVT-3101 and a handful of late-stage trials as future engines, yet those assets remain pre-commercial and, by definition, unproven at scale. The gap between the polished platform story and the filed reality is wide enough to drive a clinical trial protocol through.

Filings show Roivant’s balance sheet is structurally dependent on its cash pile: assets of $5.71 billion, liabilities of $416.3 million, and equity of $4.53 billion. Operating cash flow for the period was $-750.3 million, while capex was a mere $8.2 million-suggesting the company is in capital preservation mode rather than growth mode. Diluted EPS came in at $-0.54 on 693.9 million weighted average shares outstanding. The one metric that looks healthy is cash at $1.42 billion, but that figure is shrinking faster than a haemophiliac in a knife fight and is already down from prior quarters. Notably, the company’s 10-K notes that FDA rule changes around laboratory-developed tests may influence future pricing and purchasing patterns once products are approved, adding another layer of regulatory risk to an already thin revenue base.

The company’s product pipeline page highlights Vtama, RVT-3101, and a suite of programmes in late-stage clinical trials, but the SEC filings do not yet provide granular revenue segmentation that would allow investors to see which products are driving (or draining) the numbers. The 10-K does, however, formally disclose that the company’s cash burn is material and that R&D remains the primary cost centre. Until such time as Vtama’s sales scale meaningfully beyond $21 million per quarter-or one of the late-stage assets secures approval and launch-the company’s revenue story remains a promise rather than a proof point.

For chart watchers, the company’s shares trade on the New York Stock Exchange under the ticker ROIV, but the evidence set here does not include any trading volumes, price ranges, or analyst ratings, so any attempt to infer momentum from price action would be speculative. The SEC filings do, however, provide a clear view of the company’s operating mechanics: thin revenue, heavy burn, and a management desks that has recently seen insiders file Forms 4 disclosing multi-million-dollar share sales. If the goal is to close the chasm between the polished story and the filed reality, the company will need to either materially expand Vtama’s revenue footprint or bring one of its late-stage assets to market with pricing and uptake that can offset the $750.3 million annual cash burn.

Evidence gaps remain: segment-level revenue breakdowns, regional sales splits, payer mix, and the cadence of future filings or approvals are not disclosed in the sourced materials. The company’s pipeline page and trials portal are public-facing marketing materials and do not themselves constitute audited financial disclosures or regulatory approvals. Until such disclosures arrive, investors are left parsing headline sales numbers ($21 million for Vtama) against operating cash burn ($750.3 million) and hoping the gap narrows faster than the company’s cash pile.